Biotech ETFs Look to Claw Back After Shutdown Slump

Biotech’s Big Four also dominate the Market Vectors Biotech ETF (NYSEArca: BBH). BBH is far smaller than IBB with $435.7 million in assets, but the Market Vectors offering has seen rapid growth this year, hauling in $194 million of its current AUM total.

BBH has also slightly outpaced IBB with a year-to-date gain of 46.7%. In order, Gilead, Amgen, Celgen and Biogen combine for almost 42% of BBH’s weight. Alone, Gilead is 14.1% of BBH’s weight. S&P also rates BBH market weight.

BBH currently trades around $81.70 and needs to get back to $84 to reclaim its pre-shutdown high. BBH charges 0.35% per year while IBB charges 0.48%.

Market Vectors Biotech ETF